(trade name Sirturo)
- Bedaquiline is interestingly the first Tuberculosis drug that has been approved by Food and Drug Administration (FDA) in over 40 years.
- Bedaquiline is perhaps the first drug that can eradicate bacteria of tuberculosis from the patient's sputum and make him non-infectious.
- Bedaquiline can dramatically improve outcomes of patients suffering from multi-drug resistant tuberculosis (MDR-TB).
- In 2014, 9.6 million people were affected by tuberculosis infection and there were almost 1.5 million TB-related deaths worldwide.
, a diaryl quinoline drug has been used as the first
in the treatment of pulmonary MDR-TB for more than 40 years
The drug acts by blocking the ATP synthase enzyme
of the bacteria. This enzyme is used by the bacteria to generate energy, without the ability to generate energy, the tubercle bacteria die and
the patient improves. Bedaquiline
is interestingly the
first TB drug that has been approved by Food and Drug Administration (FDA) in
over 40 years.
perhaps the first drug that can eradicate bacteria of tuberculosis from the patient's sputum and make him non-infectious. This drug can dramatically improve outcomes of patients suffering from multi-drug resistant tuberculosis (MDR-TB).
‘Bedaquiline is perhaps the first drug that can eradicate bacteria of tuberculosis from the patient's sputum and make them non-infectious. The drug can dramatically decrease the morbidity of the disease and deaths from it.’
The drug can reduce the number of people
dying from tuberculosis
. This drug has a huge potential and can have
a very positive impact on controlling the spread of TB in the community. Tuberculosis
is a communicable and
infectious disease with one third of the world's population exposed to it. In
2014, 9.6 million people were affected by this infection and there were almost 1.5 million TB-related
Tuberculosis is caused by a
bacteria called Mycobacterium tuberculosis.
mainly spread through air
when the infected person sneezes, coughs or
talks and the bacteria usually attacks the lungs but can also damage other parts
of the body like the kidney, spine and the brain.
include bad persistent cough, chest
pain, coughing up of blood or sputum, weakness, weight loss, chills, fever and
sweating in the night. Latent TB infection
occurs when the person breathes
the TB bacteria but does not provide any symptoms of tuberculosis.
) is a form of tuberculosis
which occurs due to the resistance caused by the bacteria to the first-line
(isoniazid and rifampicin) used in tuberculosis treatment. First
line anti-TB drugs
are more effective and produce less toxic effects while Second
line anti-injectable agents
like kanamycin, amikacin, capreomycin and streptomycin
are less effective
and may provide more toxic effects. Second line drugs are commonly used in the
treatment of MDR-TB. There are also third line drugs like drugs from the
Fluoroquinolones group such as Levofloxacin
is carried out by two kinds of tests namely tuberculin skin test
tuberculin skin test ) by injecting a small amount of fluid
called tuberculin into the skin in the lower part of the arm and TB blood
which is also known as
interferon gama release assays (IGRA) measures the patient's
immune system reaction to M. tuberculosis
More About Bedaquiline in
Bedaquiline in combination with at least three other TB drugs is used to treat pulmonary MDR
-TB in adults. It is also used when other drugs cannot
be used because of their side effects.
According to a recent release,
of Bedaquiline for MDR- TB and XDR-TB has been rolled out
under the Revised National Tuberculosis Control Programme
and is part of co-ordinated programme
between the government and Johnson & Johnson. The
drug will be made available in six public hospitals
Mumbai, Chennai, Guwahati and Ahmedabad.
Sanjiv Navangul, MD of Janssen India, the pharma arm of
Johnson & Johnson which has manufactured the drug, also stated that
the roll out of the drug through the government-run control program on 600 patients
will be enrolled for the next six to nine months across the country. And after
the review of clinical data the access programme will be expanded worldwide.
the cost of the drug has not yet been decided, the report states that Janseen
is believed to be offering the drugs through a tiered-pricing structure, for example they have priced it as $3,000 for middle-income
countries and $900 for low-income countries.
concentrate efforts mainly on reducing the risk of uninfected
people who are exposed to people with TB, by reducing the amount of tubercle
bacilli in air and use of respiratory protective equipment. Hospitals and
clinics should also take precautions to prevent the spread of tuberculosis by
setting up an infection control plan which helps in prompt detection and
treatment for the affected people. Early vaccination with BCG vaccine
(which stands for Bacillus
Calmette-Guérin vaccine) protects children against tuberculosis.
is recognized on March 24
every year and "Unite
to end TB" is the theme for 2016.